The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients.


Journal

Diabetes & metabolism
ISSN: 1878-1780
Titre abrégé: Diabetes Metab
Pays: France
ID NLM: 9607599

Informations de publication

Date de publication:
07 2022
Historique:
received: 18 10 2021
revised: 11 02 2022
accepted: 11 03 2022
pubmed: 28 3 2022
medline: 3 8 2022
entrez: 27 3 2022
Statut: ppublish

Résumé

Diagnosis of nonalcoholic steatohepatitis (NASH) relies on liver biopsy. Noninvasive tools would be useful to target patients to refer for a biopsy. We aimed to determine the diagnostic value of the triglycerides and glucose (TyG) index, an insulin-resistance indicator, to predict NASH. Our study included grade II-III obese patients aged 18-65 years undergoing bariatric surgery and included in the COMET (COllection of MEtabolic Tissues) biobank (NCT02861781). Liver biopsies performed during bariatric surgery were collected from the biobank along with blood derivatives. Biopsies were analysed according to the steatosis, activity and fibrosis (SAF) scoring system to diagnose NASH, nonalcoholic fatty liver disease (NAFLD), and fibrosis. Logistic regression models were performed to identify factors predicting NASH, NAFLD, and fibrosis. Of 238 analysed subjects (mean age 43±12 years, 33.6% men), 29% had type 2 diabetes. Steatosis was present in 67.2%, while NASH and advanced fibrosis (stage F3) were diagnosed in 18.1% and 2.9% respectively. TyG index was independently associated with NASH (odds ratio (OR): 4.7 [95% confidence interval: 2.3;9.5] P < 0.0001), NAFLD (OR: 2.0 [1.1;3.7] P = 0.03) and stages 2-3 fibrosis (OR: 4.0 [1.5;10.8] P = 0.007). NASH was also predicted by gamma-glutamyl transferase (GGT) with an area under the ROC curve: 0.79 [0.71;0.87 P = 0.04] for GGT and TyG index combined. In our cohort of severely obese patients, TyG index, when associated with GGT level, exhibited high diagnostic performance to predict NASH. Although validation in larger populations is needed, this result may be of considerable clinical value to predict need for liver biopsy.

Identifiants

pubmed: 35339664
pii: S1262-3636(22)00028-3
doi: 10.1016/j.diabet.2022.101345
pii:
doi:

Substances chimiques

Biomarkers 0
Triglycerides 0
Glucose IY9XDZ35W2

Types de publication

Clinical Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101345

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no competing interests

Auteurs

Benjamin Rivière (B)

Pathology Department, CHU Montpellier, Univ Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France.

Audrey Jaussent (A)

Clinical research and epidemiology unit, CHU Montpellier, Univ Montpellier, 39 avenue Charles Flahault, 34295 Montpellier, France.

Valérie Macioce (V)

Clinical research and epidemiology unit, CHU Montpellier, Univ Montpellier, 39 avenue Charles Flahault, 34295 Montpellier, France.

Stéphanie Faure (S)

Hepato-gastroenterology department, CHU Montpellier, Univ Montpellier, 34295 Montpellier, France.

Nicolas Builles (N)

Biological Resources Center; Tissue Bank, CHU Montpellier, Univ Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France.

Patrick Lefebvre (P)

Endocrinology Department, CHU Montpellier, Univ Montpellier, 371 Av du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France.

Philippe Géraud (P)

Clinical Investigation Center 1411, INSERM, CHU Montpellier, Univ Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France.

Marie-Christine Picot (MC)

Clinical research and epidemiology unit, CHU Montpellier, Univ Montpellier, 39 avenue Charles Flahault, 34295 Montpellier, France; Clinical Investigation Center 1411, INSERM, CHU Montpellier, Univ Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France.

Sandra Rebuffat (S)

Biocommunication in Cardio-Metabolism (BC2M), University of Montpellier, 15 avenue Charles Flahault, 34093 Montpellier cedex 5, France.

Eric Renard (E)

Endocrinology Department, CHU Montpellier, Univ Montpellier, 371 Av du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France; Clinical Investigation Center 1411, INSERM, CHU Montpellier, Univ Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France.

Valérie Paradis (V)

DHU UNITY, Pathology Department, Hôpital Beaujon, AP-HP, Clichy, France.

Marie-Dominique Servais (MD)

Servier, 50 rue Carnot, 92284 Suresnes Cedex, France.

Nathalie de Preville (N)

Servier, 50 rue Carnot, 92284 Suresnes Cedex, France.

David Nocca (D)

Department of Digestive Surgery, CHU Montpellier, Univ Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France.

Anne-Dominique Lajoix (AD)

Biocommunication in Cardio-Metabolism (BC2M), University of Montpellier, 15 avenue Charles Flahault, 34093 Montpellier cedex 5, France.

Georges-Philippe Pageaux (GP)

Hepato-gastroenterology department, CHU Montpellier, Univ Montpellier, 34295 Montpellier, France.

Florence Galtier (F)

Endocrinology Department, CHU Montpellier, Univ Montpellier, 371 Av du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France; Clinical Investigation Center 1411, INSERM, CHU Montpellier, Univ Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France. Electronic address: f-galtier@chu-montpellier.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH